Imaging on cells (HCA/HCS) and on animals are now possible. In this article, is reported both cell and animal imaging onAlpha-synuclein (αSYN) aggregation, a pivotal role in the Parkinson disease. Oligomerization of αSYN was monitored noninvasively with bioluminescence imaging in the mouse striatum and substantia nigra up to 8 months after injection.
The split firefly luciferase-αSYN complementation assay will increase our insight in the role of αSYN oligomers in synucleinopathies and opens new opportunities to evaluate potential αSYN-based neuroprotective therapies.
Curated from www.jneurosci.org